SUBSCRIBE
SUBSCRIBE

Eledon Pharmaceuticals

NEWS
Pictured: Illustration of gloved hands using tools
Biotech Bay
Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant
Tegoprubart, Eledon Pharmaceuticals’ experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following the first-ever transplant of a kidney from a genetically modified pig to a human.
March 22, 2024
 · 
4 min read
 · 
Tyler Patchen
IN THE PRESS
Business
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 11, 2024
 · 
1 min read
Press Releases
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 5, 2024
 · 
5 min read
Press Releases
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 15, 2024
 · 
6 min read
Press Releases
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024
 · 
4 min read
Drug Development
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 3, 2024
 · 
1 min read
Drug Development
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
June 3, 2024
 · 
5 min read
Business
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 9, 2024
 · 
7 min read
Drug Development
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 9, 2024
 · 
2 min read
Biotech Beach
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 7, 2024
 · 
3 min read
Biotech Beach
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 7, 2024
 · 
6 min read
Load More
JOBS